SignalRx Pharmaceuticals Inc., Crystec Ltd., and ADYA Consulting SAGL are pleased toannounce a new collaboration to develop an inhaled dry powder formulation of SF2523 for the treatmentof pulmonary fibrosis, lung cancer and SARS-CoV-2 related illnesses. SignalRx SF2523 is a novel, small molecule dual PI3K-BRD4 inhibitor with a synergistic action on twopathways associated with the development of lung cancer and idiopathic pulmonary fibrosis (IPF). Combinedinhibition of both the PI3K and BRD4 pathways maximizes cellular effects in tumor and fibrosis models, andenables higher dosing with greatly improved tolerability. As such, SF2523 offers potential advantages overother drugs in the market and in development.
The post New collaboration to develop an inhalable SF2523 for lung cancer, lung fibrosis and SARS-CoV-2 appeared first on Pharma Mirror Magazine.
